Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: A double blind randomized controlled trial

Clinical Infectious Diseases

Volumn 59, Issue 9, 2014, Pages 1246-1255

  Hung, Ivan F N ^a   Zhang, Anna J ^a   To, Kelvin K W ^a   Chan, Jasper F W ^a   Li, Can ^a   ShunZhu, Hou ^a   Li, Patrick ^a   Li, Clara ^a   Tuen Ching, Chan ^a   Cheng, Vincent C C ^a   HungChan, Kwok ^a   YungYuen, Kwok ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

imiquimod; immunogenicity; influenza; intradermal; vaccine

Indexed keywords

ANTIBIOTIC AGENT; IMIQUIMOD; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTHRALGIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ECCHYMOSIS; FEMALE; FEVER; GEOMETRY; HEMAGGLUTINATION INHIBITION; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; OUTCOME ASSESSMENT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INDURATION; SKIN REDNESS; VIRUS STRAIN; BLOOD; CHEMISTRY; IMMUNOLOGY; INFLUENZA VIRUS A; INFLUENZA, HUMAN; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TOPICAL DRUG ADMINISTRATION; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTIBODIES, VIRAL; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED;

EID: 84913602317     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu582     Document Type: Article

References (35)

1. Fleming DM, Elliot AJ. The impact of influenza on the health and health care utilisation of elderly people. Vaccine 2005; 23:S1-9.
2. Cheng VC, To KK, Tse H, et al. Two years after pandemic influenza A/2009/H1N1: what have we learned. Clin Microbiol Rev 2012; 25:223-63.
3. World Health Organization Influenza (Seasonal) Fact Sheet No. 211, 2014. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed 18 March 2014.
4. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
5. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterization of viral genome. Lancet 2013; 381:1916-25.
6. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-35.
7. Hung IF, Levin Y, To KK, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012; 30:6427-35.
8. Rümke HC, Richardus JH, Rombo L, et al. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis 2013; 26:348.
9. Reallocating Influenza A (H1N1) 2009 Monovalent Vaccine. Available at: http://www.cdc.gov/h1n1flu/vaccination/reallocating.htm. Accessed 18 March 2014.
10. Weldon WC, Zarnitsyn VG, Esser ES, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One 2012; 7:e41501.
11. Zhang AJ, Li C, To KK, et al. TLR7 agonist imiquimod in combination with influenza vaccine expedite and augment humoral immune responses against influenza A(H1N1)pdm09 infection in BALB/c mice. Clin Vaccine Immunol 2014; 21:570-9.
12. Zuber AK, Bråve A, Engström G, et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 2004; 22:1791-8.
13. Chen XZ, Mao XH, Zhu KJ, et al. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells. Arch Dermatol Res 2010; 302:57-65.
14. Othoro C, Johnston D, Lee R, et al. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect Immun 2009; 77:739-48.
15. Hung IF, To KK, Lee CK, et al. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 2010; 51:274-9.
16. Chan KH, To KK, Hung IF, et al. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin Vaccine Immunol 2011; 18:867-73.
17. Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines, 1997. CPMP/BWP/214/96 (circular 96-0666):1-22. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003945.pdf. Accessed 14 November 2013.
18. International Classification of Diseases, Ninth Revision, Clinical Modification. Available at: http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed 18 March 2014.
19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
20. To KK,Wong SS, Li IW, et al. Concurrent comparison of epidemiology, clinical presentation and outcome between adult patients suffering from the pandemic influenza A (H1N1) 2009 virus and the seasonal influenza A virus infection. Postgrad Med J 2010; 86:515-21.
21. Wang H, Fu C, Li K, et al. Influenza associated mortality in Southern China, 2010-2012. Vaccine 2014; 12:973-8.
22. Cate TR, Kasel JA, Couch RB, et al. Clinical trials of bivalent influenza A/New Jersey/76-A/Victoria/75 vaccines in the elderly. J Infect Dis 1977; 136(suppl):S518-25.
23. Van Damme P, Oosterhuis-Kafeja F, Van derWielen M, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-9.
24. Song JM, Kim YC, Lipatov AS, et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B-and T-cell responses in mice. Clin Vaccine Immunol 2010; 17:1381-9.
25. Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010; 184:2518-27.
26. Pearton M, Kang SM, Song JM, et al. Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines. PLoS One 2010; 5:e12410.
27. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:6333-9.
28. Yang WH, Dionne M, Kyle M, et al. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. Vaccine 2013; 31:4389-97.
29. Geeraedts F, Goutagny N, Hornung V, et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008; 4:e1000138.
30. Eisenbarth SC, Williams A, Colegio OR, et al. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 2012; 484:510-3.
31. Mark KE, Corey L, Meng TC, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis 2007; 195:1324-31.
32. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-7.
33. Roukens AH, Vossen AC, Boland GJ, et al. Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). Vaccine 2010; 28:4288-93.
34. Hung IF, Levin Y, To KK. Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine 2012; 30:2707-8.
35. Influenza Vaccination Helps. Available at: http://www.chp.gov.hk/en/exhibition-details/2740/0.html. Accessed 18 March 2014.